NORAD and acute myeloid leukemia: Currently, there is relatively limited research on the mechanisms of NORAD in AML. Masoud Eslami et al. demonstrated that high NORAD expression is a critical factor associated with poor prognosis in non-M3 AML patients, based on comparisons of NORAD expression levels in clinical samples from non-M3 AML patients and healthy individuals (Masoud Eslami et al., 2021).